Axsome Therapeutics (AXSM) Research & Development (2015 - 2026)

Axsome Therapeutics has disclosed Research & Development across 12 years of filings, most recently posting $52.7 million for Q1 2026.

• Research & Development for Q1 2026 came in at $52.7 million, up 17.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $145.0 million (down 25.66% YoY), and the FY2025 annual result was $183.3 million, down 2.03% from the prior year.
• Research & Development came in at $52.7 million for Q1 2026 at Axsome Therapeutics, up from $2.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $55.0 million in Q4 2024 to a low of $2.6 million in Q4 2025.
• The 5-year median for Research & Development is $30.8 million (2023), against an average of $31.3 million.
• Across the five-year window, Research & Development jumped 142.23% in 2024 and plunged 95.27% in 2025, its largest moves.
• Axsome Therapeutics' Research & Development stood at $14.7 million in 2022, then jumped by 109.64% to $30.8 million in 2023, then jumped by 78.57% to $55.0 million in 2024, then slumped by 95.27% to $2.6 million in 2025, then surged by 1926.04% to $52.7 million in 2026.
• The last three Research & Development figures came in at $52.7 million (Q1 2026), $2.6 million (Q4 2025), and $40.2 million (Q3 2025), per Business Quant data.